Solid tumors are increasingly recognized as a systemic disease that is manifested by changes in DNA, RNA, proteins and metabolites in the blood. Whereas many studies have reported gene mutation events in the circulation, few studies have focused on epigenetic DNA methylation markers. To identify DNA methylation biomarkers in peripheral blood for ovarian cancer, we performed a two-stage epigenome-wide association study. In the discovery stage, we measured genome wide DNA methylation for 485 000 CpG sites in peripheral blood in 24 epithelial ovarian cancer (EOC) cases and 24 age-matched healthy controls. We selected 96 significantly differentially methylated CpG sites for validation using Illumina's Custom VeraCode methylation assay in 206 EOC cases and 205 controls and 46 CpG sites validated in the independent replication samples. A set of 6 of these 46 CpG sites was found by the receiver operating characteristic analysis to have a prediction accuracy of 77.3% for all EOC (95% confidence interval: 72.9-81.8%). Pathway analysis of the genes associated with the 46 CpG sites revealed an enrichment of immune system process genes, including LYST (cg16962115, FDR = 1.24E−04), CADM1 (cg21933078, FDR = 1.22E−02) and NFATC1 (cg06784563, FDR = 1.46E−02). Furthermore, DNA methylation status in peripheral blood was correlated with platelet parameters/coagulation factor levels. This study discovered a panel of epigenetic liquid biopsy markers closely associated with overall immunologic conditions and platelet parameters/coagulation systems of the patients for detection of all stages and subtypes of EOC.
Introduction
Ovarian cancer is the most lethal gynecologic cancer world wide (1) . The two main reasons for the high death rate are lack of early detection and chemoresistance (2) . Although ovarian cancer patients respond to initial chemotherapy, approximately 25% of patients develop chemotherapeutic drug resistance within 6 months (3). Extensive investigations in the tumor tissues have revealed heterogeneous genetic and epigenetic alterations underlying ovarian cancer development and progression.
Developing effective early detection biomarkers, especially in the circulation, is critically needed for improving the outcome of women with ovarian cancer.
It is well established that tumor cells lyse and release DNA fragment (cfDNA or cell free DNA) as well as other molecules such as miRNA and cytokines to circulation (4) . These tumor associated cfDNAs in the circulation are the basis for mutation detection in genes known to be altered in cancer especially in the advanced stages when mutant DNAs are relatively abundant in the blood for detection. Mutation detection for early stage cancer is challenging due to the limited release of tumor cfDNA in the circulation when tumors are restricted locally. In addition, early tumor driving events may be epigenetic in nature, and defy mutation-based detection.
The recent successes in check-point immunotherapy have revived the recognition that cancer is a systemic disease that can be directly affected by the immune system (5) . Emerging evidence has revealed that specific types of immune cells play a profound role in ovarian cancer cell proliferation and metastasis (6) (7) (8) . Therefore, immune cells may represent a window to explore cancer pathogenesis and physiological homeostasis. Events associated with the immune system may be ideal biomarkers for cancer, especially in early stages. It is conceivable that genetic or epigenetic alterations in tumor cells would trigger immune surveillance and immune cells would undergo epigenetic reprogramming in order to counteract the appearance of cancer cells.
Recently, peripheral blood-derived DNA methylation profiles have been found to be associated with several cancer types such as breast, lung, gastric, ovarian and pancreatic cancer (9) (10) (11) (12) (13) (14) (15) . Previous epigenome wide association studies of blood-based DNA methylation biomarkers for ovarian cancer risk were performed with a low density platform with coverage of 27 000 CpGs (12, (16) (17) (18) . Thus, we undertook the present study to explore the potential value of leukocyte DNA methylation in epithelial ovarian cancer (EOC). We conducted a two-stage case-control study basing on the epigenome-wide association study in Chinese EOC patients. In the discovery stage, 450 000 CpGs were scanned in genome-wide methylation array, and differentially methylated CpG sites were selected for validating in validation stage.
Materials and Methods

Study population
Ovarian cancer cases were women aged 25-85 years with histologically confirmed primary EOC between 2007 and 2013 in Tianjin Medical University Cancer Hospital. Patients with a previous medical history of cancer or blood transfusion within preceding 6 months were excluded. Patient blood samples were collected in the operating room and the values of blood cell counts and coagulation factors were obtained from the routine blood test and routine coagulation test that was conducted within a week before operation. Controls were cancer-free subjects from communities in Tianjin, who had no previous diagnosis of cancer and frequencymatched (with 5-year interval) to cases on age. Each subject completed questionnaires (including demographic information, health conditions, lifestyle and dietary habits) and provided blood samples for research. This study was approved by the Institutional Review Board of Tianjin Medical University Cancer Institute and Hospital, and informed consent was obtained for use of clinical specimens for research.
In the discovery stage, 24 EOC cases (12 cases with FIGO stages I-II and 12 cases with FIGO stages III-IV) and age-frequency matched controls were randomly selected for genome-wide methylation profiling. In validation stage, 206 EOC cases and 205 age-frequency matched controls were included in validation of the CpG sites selected in phase I.
DNA extraction and bisulfate conversion
Genomic DNA from sample collections was extracted from leukocytes by Qiazen DNA Blood Mini Kit (Qiazen, Valencia, CA), and stored at −80°C until bisulfite modification. By treating the genomic DNA using the bisulfate conversion kit of EZ-96 DNA Methylation-Gold Kit (D5008) (Zymo Research, Orange, CA) according to the manufacturer's protocol, the unmethylated cytosine was converted into uracil and the methylated cytosine remained unchanged. Bisulfite converted DNA was stored at −20°C, and used within one week after conversion.
Genome-wide methylation profiling
In the discovery stage, the genome-wide methylation profiling was conducted utilizing Illumina Infinium HumanMethylation450 BeadChip (San Diego, CA). We imaged the arrays with the Illumina BeadArray TM Reader and obtained the data using Illumina's GenomeStudio software. All samples passed quality control test, which included staining controls, extension controls, target removal controls, hybridization controls, bisulfate conversion controls, specificity controls, negative controls and non-polymorphic binding controls. Background normalization was performed with negative control bead in each well. DNA methylation value (β-value) of each CpG site was ranged from 0 (unmethylated) to 1 (methylated), represented by the relative ratio of methylated allele signals to total fluorescent signals after subtracting background intensity.
Validation of selected CpG loci
In validation stage, the Illunima's Custom VeraCode methylation assay (96-plex) was designed for validation studies of 96 selected CpG loci. Illunima's BeadXpress Reader scanner and Illumina's GenomeStudio were used to scan the beadchip and obtain data, respectively. A quality control test was completed including nine internal controls (allele-specific extension controls, PCR uniformity controls, extension gap controls, gender controls, first hybridization controls, second hybridization controls, negative controls and contamination detection controls). One CpG site (cg26366833) failed to genotype in validation; therefore, 95 CpG sites passed quality control, and the calculation of methylation value was the same to the HumanMethylation450 BeadChips. Thirteen samples were examined twice for technical replication, high correlation was observed between the replication samples (r 2 > 0.98).
Gene expression analysis
The gene expression microarray data is publicly available from Gene Expression Omibus (GEO, http://www.ncbi.nlm.nih.gov/geo/, Accession number GSE31682), and consisted of 48 ovarian cancer cases and controls (19) . The difference of gene expression of the three genes in blood cells between cases and controls was carried out using independent t-test.
Statistical analysis
To compare the demographic characteristics between cases and controls, χ 2 test and independent t-test were used for categorical variables and continuous values, respectively. In the initial discovery stage, the difference of median β-value between cases and controls for each CpG site was carried out using independent t-test. Stratified analysis according to stage of EOC (I-II, III-IV) was also performed. We then selected 96 top differentially methylated CpG sites from the genome-wide scan for validation as following: (a) P < 1.0 × 10 -4 ; (b) the same direction between I-II EOC cases and III-IV EOC cases when compared with controls; and (c) available for epigenotyping using Illunima's Custom VeraCode methylation assay. In the validation stage, an independent t-test was used to assess the difference of methylation values between study groups. The Pearson correlation analysis was conducted to evaluate the correlation between DNA methylation and blood cell counts/coagulation factors. To correct for multiple testing, Benjamini and Hochberg correction method was utilized to calculate the false discovery rate (FDR), and FDR < 0.05 was considered to be significant. Furthermore, to evaluate the classifier performance of differentially methylated CpG sites in validation stage, we utilized a logistic regression model to build the predicting model of receiver operating characteristic curves. DNA methylation markers were selected using stepwise and manual selection method.
Additionally, to identify the commonality of genes within biological pathways, we utilized the DAVID gene ontology tool for the pathway enrichment analysis, which was conducted for the genes near the differentially methylated CpG sites associated with ovarian cancer risk. All Abbreviations EOC epithelial ovarian cancer FDR false discovery rate analyses were carried out using SAS version 9.3 (SAS Institute, Cary, NC) and R version 3.1.2.
Results
To identify differential DNA methylation in peripheral blood leukocytes in ovarian cancer, we conducted two stage case-control epigenome-wide association study (EWAS). A flowchart of the study design was shown in Figure 1 . To identify the commonality of the 56 genes putatively regulated by the 46 different methylated CpG sites, we carried out pathway enrichment analysis utilizing the DAVID gene ontology ( Figure 5 ). The top fold enrichment pathway was leukocyte mediated cytotoxicity and there were two genes included in the pathway were LYST (cg16962115, FDR = 1.24E−04) and CADM1 (cg21933078, FDR = 1.22E−02). Most of the enriched pathways involved immune system process related pathways; we found that NFATC1 (cg06784563, FDR = 1.46E−02) was included in immune system in Reactom pathway database (Supplementary Figure 9 , available at Carcinogenesis Online). We found that the expression of CADM1 (P = 2.87E−04) in blood cells was significantly lower in EOC patients than controls. But no significant expression differences were observed in LYST (P = 0.30) and NFATC1 (P = 0.25) (Supplementary Figure 9 , available at Carcinogenesis Online). In addition, we evaluated the correlation between differentially methylated CpG sites and blood cell counts/coagulation factors (Supplementary Table 5 , available at Carcinogenesis Online). No significant correlation was observed between DNA methylation and blood cell counts except platelet count (Supplementary Figure 10 , available at Carcinogenesis Online). We found that several CpG sites were correlated with platelet parameters and coagulation factors ( Figure 6 ). Five platelet parameters (PLT: platelet count, PCT: plateletcrit, MPV: mean platelet volume, PDW: platelet distribution width and PLCR: platelet large cell ratio) and four coagulation factors (PT: prothrombin time, D-dimer, Fbg: plasma fibrinogen and AT III: Antithrombin III) were included in the correlation analysis. We found that four CpG sites (cg06784563, cg16541275, cg00207226 and cg00066854) were correlated with all the platelet parameters. For coagulation factors, there was no one correlated with all of the four coagulation factors. DNA methylation level of cg22441770 was correlated with both PT and AT III and there was 11 CpG sites were correlated with D-dimer. 
Discussion
In this two stage case-control epigenome-wide association study, we identified 46 novel CpG sites that were significantly associated with ovarian cancer in Han Chinese women. We also constructed a relatively high accuracy risk prediction model using six CpG sites, especially in early stage ovarian cancer. Pathway analysis using the genes with 46 significantly differentially methylated sites showed that they are parts of the immune system-related pathways. OC risk-associated differentially methylated CpG sites were not correlated with blood cell counts, but an association was observed with platelet parameters/coagulation factors. To our knowledge, this is the first report that revealed the correlation between DNA methylation in peripheral blood leukocyte and platelet parameters/coagulation factors.
Although the DNA methylation markers in peripheral blood have been reported in several types of cancers including breast, head and neck, ovarian, gastric, colorectal, and pancreatic cancer, the biological significance is uncertain (20) . It is reported that DNA methylation was associated with lifestyle factors, dietary intake, and environmental exposure (21) . Recently, increasing studies have been shown the relationship between DNA methylation with smoking and BMI (22, 23) . Previous studies speculated that the change of DNA methylation in peripheral blood may be due to the shift in blood cell components. To reveal the mechanism, Koestler et al. compared the DNA methylation between the subpopulations of leukocyte (including B cells, granulocytes, monocytes, NK cells, CD4+ T cells, CD8+ T cells and Pan-T cells) that were isolated from normal human peripheral blood leukocyte, they identified 50 CpG sites were significantly differentially methylated between the subpopulations of leukocytes (11) . However, the 50 CpG sites were not statistically significant in our study, which is consistent with the previous report in breast cancer (9) . In our study, DNA methylation sites related to ovarian cancer were not associated with leukocyte subpopulations. Interestingly, we found that DNA methylation in peripheral blood was correlated to platelet parameters and coagulation factors. Circulating blood platelets were reported to play a key role in the process of hemostasis, immunity, inflammation and cancer development/ metastasis (8, 24) . In ovarian cancer, it is reported that platelet count was associated with EOC prognosis (25) and platelets could directly increase the proliferation of ovarian cancer cells (6) . Global changes in DNA methylation during epithelial mesenchymal transition (EMT) in ovarian cancer could be induced by TGFβ1 (26) and the TGFβ1 secreted from platelet enhances an EMT in cancer cells (27) . However, the mechanism of the relationship between platelet and DNA methylation in peripheral blood was still unknown, further studies are warranted.
In our study, we identified that genes with OC risk-associated differentially methylated CpG sites were involved the immune system process related pathways, including leukocyte mediated cytotoxicity, cell killing and immune effector process. Three genes, NFATC1 (cg06784563), LYST (cg16962115) and CADM1 (cg21933078) were enriched in the immune system process pathway. Cg06784563 was located at 5ʹ promoter flanking region of NFATC1 that encodes nuclear factor of activated T-cells 1. NFAT proteins have been reported to have important functions in the immune system (28) and NFAT transcription factors have crucial role in many developmental programs including cancer (29) . In ovarian cancer, NFACT1 was significantly overexpressed in tumor tissues compared to paired normal control tissues and can promote proliferation up-regulating c-myc through activation of ERK1/2/p38/MAPK signal pathway in vitro (30) . Cg21933078 was located at 15kb upstream of CADM1 on chromosome 11, CADM1 is a cell adhesion molecule and identified as a tumor suppressor in previous studies (31, 32) . The decreased expression of CADM1 may conceivably be caused by promoter methylation thus promoting the tumor proliferation/invasion (31, 32) . In ovarian carcinoma, the downregulation of CADM1 may serve as a biomarker of poor prognosis (33) . CADM1 have a novel function in suppression of metastasis by sensitizing tumor cells to immune surveillance mechanisms and CADM1 loss is an important step in cancer immunoediting (34) . Cg16962115 was located at 35 kb upstream of LYST that encodes lysosomal trafficking regulator at 1q42.3. Mutations in LYST were associated with Chediak-Higashi syndrome (35) . There was no report about LYST on ovarian cancer or other cancers. Further studies are warranted to understand the implication of this gene in ovarian cancer.
Previous epigenome-wide association studies in ovarian cancer have identified differentially methylated CpG sites in peripheral blood (12, 16, 17) . However, none of them reached our selection criteria for validation (P < 1.0 × 10 -4 ). These discrepant results were probably due to the following reasons: (1) the discovery stage of the previous studies was based on the Illumina's 27K Methylation Beadchip and the coverage of 450K that we used was much greater than previous studies. Of the 96 CpG sites that were selected for validation in our study, only one CpG site was included in the 27K methylation beadchip. (2) The populations of previous studies were European and our study population is Asian. It is well recognized that important differences exist between ethnic populations (36) . In a recent GWAS study, we also found that the ovarian cancer risk loci discovered by GWAS in European population were not replicated in the Han Chinese population (37) .
In summary, we have identified a set of blood-derived DNA methylation signatures that may be associated with EOC risk. Thus profiling of DNA methylation in peripheral blood may serve as novel tools for risk assessment and early detection in ovarian cancer. Validation study in large prospective cohorts and in-depth biological mechanistic research will be needed to validate these new biomarkers and develop strategies of epigenome therapy of ovarian cancer for precision medicine. 
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